SARS-CoV-2 (COVID-19) Spike Antibody (biotin)

Infectious Disease, COVID-19

Anti-SARS-CoV-2 (COVID-19) Spike antibody (3525) was raised against a peptide corresponding to 20 amino acids near the carboxy terminus of SARS-CoV-2 (COVID-19) Spike glycoprotein.

The immunogen is located within the last 50 amino acids of SARS-CoV-2 (COVID-19) Spike protein.

SARS-CoV-2 (COVID-19) Spike Antibody is affinity chromatography purified via peptide column.

IgG

SARS-CoV-2 (COVID-19) Spike Antibody is supplied in PBS containing 0.02% sodium azide.

SARS-CoV-2 (COVID-19) Spike antibody can be stored at 4˚ C for three months and -20˚ C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.

S

1791269090

Optimal dilutions for each application to be determined by the researcher.

surface glycoprotein

Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

Hui et al. Int J Infect Dis. 2020; 91:264-266.

Lee et al. J Virol. 2006; 80(8):4079-87.

Wrapp et al. Science. 2020.

Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, Baxter-Stoltzfus A, Laurence J. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Transl Res. 2020; 220:1-13. doi: 10.1016/j.trsl.2020.04.007. PMID: 32299776

Magro, et al. Docked severe acute respiratory syndrome coronavirus 2 proteins within the cutaneous and subcutaneous microvasculature and their role in the pathogenesis of severe coronavirus disease 2019. Hum Pathol. 2020 Dec; 106:106-116. doi: 10.1016/j.humpath.2020.10.002. Epub 2020 Oct 12.PMID: 33058948

Mulvey, et al. Analysis of complement deposition and viral RNA in placentas of COVID-19 patients. Ann Diagn Pathol. 2020 Jun; 46:151530. doi: 10.1016/j.anndiagpath.2020.151530. Epub 2020 Apr 25.PMID: 32387855

Singh, et al. Responses to acute infection with SARS-CoV-2 in the lungs of rhesus macaques, baboons and marmosets. Nat Microbiol. 2021 Jan; 6(1):73-86. doi: 10.1038/s41564-020-00841-4. Epub 2020 Dec 18PMID: 33340034